Sirakova V, Penkov N, Kaponov Kh
Vutr Boles. 1986;25(2):29-32.
Ebrantil has been added to the beta-blockers and/or diuretics in the treatment of 32 patients with moderate and severe hypertension under the conditions of 3-month open clinical experiment. A very good antihypertensive effect was obtained in 31.3% of the treated, moderate--in 65.6% and unsatisfactory--in 3.1%. Ebrantil does not change the heart rate and is, in fact, without any adverse effects.
在为期3个月的开放临床试验条件下，对32例中重度高血压患者，在使用β受体阻滞剂和/或利尿剂治疗的基础上加用依那普利。治疗患者中31.3%获得了非常好的降压效果，65.6%为中度效果，3.1%效果不佳。依那普利不改变心率，实际上也无任何不良反应。
Zotero 插件